ChromaCode
ChromaCode Partners With Medical College of Georgia on Non-Small Cell Lung Cancer Rapid PCR Testing
The college's department of pathology will work with the company to further validate a lung cancer genotyping assay developed using ChromaCode's HDPCR technology.
In the past year, dPCR developers launched new instruments aiming to support clinical users amid changes in nonclinical biopharma and wastewater testing use.
ChromaCode Lung Cancer Assay Shows Advantages in New Data at AMP as Company Eyes Next Applications
Premium
The firm is working with early adopters of its NSCLC kit as it develops new tests for cancer minimal residual disease monitoring and kidney transplant rejection.
ChromaCode, Protean BioDiagnostics Partner to Launch Lung Cancer Test
The test uses ChromaCode's High Definition PCR multiplexing technology and detects all National Comprehensive Cancer Network recommended variants in less than 24 hours.
ChromaCode Initiates Strategic Shift to Oncology With New Leadership, Digital PCR Lung Cancer Test
Premium
Multiplexed PCR specialist ChromaCode has hired a new CEO and chief business officer to help spearhead its transition to the oncology testing space.